Medical Oncologist
While you are on imatinib
Tests and Monitoring — While You Are on Imatinib
When you start imatinib, regular blood tests are part of the treatment, not separate from it. They tell your team whether the drug is working, whether your body is tolerating it, and whether anything needs to change.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Monitoring starts before your first dose — Baseline results give your team a point of comparison for every test that follows.
- Frequency decreases over time — Testing is most frequent in the first three months, then settles into a longer-term schedule once your results are stable.
- Your schedule depends on your diagnosis — CML requires molecular response monitoring that GIST does not — your test list reflects why you are on imatinib.
- Feeling normal does not mean normal counts — Blood cell changes can happen before any symptom appears, which is why tests continue even when you feel well.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
On imatinib, you will need regular blood counts, liver function tests, and kidney tests, plus BCR-ABL molecular tests if you have CML. NCCN and ELN guidance schedules tests most frequently in the first three months, then moves to three-monthly and six-monthly intervals. The results tell your team whether imatinib is working and whether your body is tolerating it.
Which tests are needed, how often, and what do the results mean?
| Test | How often | What it checks | Tell your team if |
|---|---|---|---|
| Complete blood count (CBC) | Every 2–4 weeks for the first 3 months, then every 3 months | White cells, red cells, and platelets — imatinib can suppress all three early in treatment | You notice unusual bruising, repeated infections, or breathlessness that is new for you |
| Liver function tests (LFTs) | Monthly for the first 3 months, then at each clinic review | Whether the liver is coping with imatinib — liver inflammation is a recognised side effect | You develop yellowing of skin or eyes, dark urine, or right-sided abdominal discomfort |
| BCR-ABL PCR (CML patients only) | At 3, 6, and 12 months, then every 6 months once stable | How deeply the cancer gene is suppressed — the main measure of whether imatinib is working | Your result is not falling as expected — your team will review the dose or consider alternatives |
| Kidney function and electrolytes | At baseline, then periodically | How well your kidneys are filtering, and key mineral levels including phosphate | New ankle swelling, muscle cramps, or a marked change in how much you are urinating |
| Typically starts | Before your first imatinib dose — baseline values are essential so later results are compared against your own normal, not a population average |
What you can do to make each test as useful as possible
- Bring a full medicines list to every appointmentInclude prescription drugs, over-the-counter tablets, supplements, and any herbal or Ayurvedic preparations. Imatinib interacts with several common medicines.
- Keep the appointment even when you feel wellBlood counts can change before symptoms appear. Feeling normal is not a reason to skip or delay a scheduled test.
- Tell the phlebotomist you are on imatinibSome labs have specific handling or timing notes for samples from patients on tyrosine kinase inhibitors.
- Ask for your results in writing each timeA personal record of your test trends helps you and your team spot changes earlier than relying on memory.
- Note new symptoms before your next testA written note — even a voice memo on your phone — is easier to recall accurately in clinic than trying to remember on the day.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How does monitoring progress from your first dose onwards?
Before your first dose: baseline testing
Blood count, liver function, kidney function, and electrolytes are measured before imatinib starts. For CML, a BCR-ABL test at diagnosis gives the reference point all future results are measured against.
First three months: frequent checks
Blood counts are checked every two to four weeks. Liver function is checked monthly. This is when tolerability is established and the dose may be adjusted if your counts fall or liver enzymes rise.
Three-month review: first response milestone
For CML, the BCR-ABL PCR at three months is the first formal check of whether imatinib is suppressing the cancer gene. ELN guidelines describe the expected response at this point; your oncologist will tell you whether your result is on track.
Six and twelve months: deeper response targets
BCR-ABL testing at six and twelve months checks whether the molecular response is deepening over time. These milestones guide decisions about whether to continue, adjust the dose, or consider a different TKI.
Long term: less frequent, still essential
Once results are stable, blood counts and molecular tests move to a three- to six-monthly schedule. Monitoring continues for as long as you are on imatinib — years in most cases — because the results guide every treatment decision.
Did you know?
Most people on imatinib for CML remain on treatment for many years, and monitoring continues throughout.
ELN recommendations state that regular molecular response testing is what makes it possible to detect a loss of response early — when the options for adjusting or switching treatment are widest.
Source: European LeukemiaNet (ELN) Recommendations for the Management of Chronic Myeloid Leukaemia
Explore 75 more Blood Cancer Targeted Medicines topics
Drug Deep Dive: Imatinib (Gleevec)
- Adjuvant Imatinib After GIST Surgery: How Many Years?
- BCR-ABL PCR Monitoring: What 'Log Reduction' and 'MR4.5' Mean
- Can You Ever Stop Imatinib? Treatment-Free Remission Explained
- Diet and Nutrition While on Imatinib
- Fertility, Pregnancy and Contraception on Imatinib
- How Does Imatinib Work? The BCR-ABL and KIT Inhibitor Explained
- How Long Does Imatinib Take to Work?
- Imatinib (Gleevec, Veenat, Imatib): The Complete Patient Guide
- Imatinib Interactions: Paracetamol, Antacids and Herbal Medicines
- Imatinib Myths: Lifelong Dependence, Fertility and Generic Quality
- Imatinib Price in India: Brand, Generic and Monthly Cost
- Imatinib Side Effects: The Complete List and Timeline
- Imatinib Success Rate and Survival: An Honest Look at the Numbers
- Imatinib for GIST: How It Differs From CML Treatment
- Imatinib in Elderly Patients and Those With Other Illnesses
- Imatinib vs Nilotinib vs Dasatinib: Choosing a CML Drug
- Muscle Cramps and Bone Pain on Imatinib: What Actually Helps
- Nausea, Stomach Upset and Weight Gain on Imatinib
- Puffy Eyes and Swollen Legs on Imatinib: Managing Fluid Retention
- Taking Imatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Imatinib
- When Imatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Imatinib? Chronic Myeloid Leukaemia and GIST
- Will Insurance or a Government Scheme Pay for Imatinib?
- Work, Travel and Daily Life on Imatinib
Drug Deep Dive: Ibrutinib (Imbruvica)
- Diarrhoea, Joint Pain and Infection Risk on Ibrutinib
- Diet and Nutrition While on Ibrutinib
- Easy Bruising and Bleeding on Ibrutinib: What Is Normal and What Is Not
- Fertility, Pregnancy and Contraception on Ibrutinib
- How Does Ibrutinib Work? The BTK Inhibitor Explained
- How Long Does Ibrutinib Take to Work?
- How Long Will You Stay on Ibrutinib?
- Ibrutinib (Imbruvica, Ibrutix): The Complete Patient Guide
- Ibrutinib Interactions: Blood Thinners, Antifungals and Fish Oil
- Ibrutinib Myths: Lifelong Treatment, Bruising and 'It's Not Real Treatment'
- Ibrutinib Price in India: Brand, Generic and Monthly Cost
- Ibrutinib Side Effects: The Complete List and Timeline
- Ibrutinib Success Rate and Survival: An Honest Look at the Numbers
- Ibrutinib With Rituximab or Venetoclax: Continuous vs Fixed-Duration Therapy
- Ibrutinib in CLL, Mantle Cell Lymphoma and Waldenstrom's
- Ibrutinib in Elderly Patients and Those With Other Illnesses
- Ibrutinib vs Acalabrutinib vs Zanubrutinib: Comparing BTK Inhibitors
- Palpitations, Atrial Fibrillation and High Blood Pressure on Ibrutinib
- Surgery and Dental Procedures on Ibrutinib: The Bleeding Rule
- Taking Ibrutinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Ibrutinib
- When Ibrutinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Ibrutinib? CLL, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia
- Will Insurance or a Government Scheme Pay for Ibrutinib?
- Work, Travel and Daily Life on Ibrutinib
Drug Deep Dive: Rituximab (MabThera)
- Diet and Nutrition While on Rituximab
- Drug, Food and Supplement Interactions With Rituximab
- Fertility, Pregnancy and Contraception on Rituximab
- Hepatitis B Reactivation and Rituximab: The Test You Must Not Skip
- How Does Rituximab Work? The Anti-CD20 Monoclonal Antibody Explained
- How Long Does Rituximab Take to Work?
- How Long Will You Stay on Rituximab?
- Low Antibodies and Repeated Infections After Rituximab
- MabThera vs Biosimilar Rituximab in India: Cost and Equivalence
- R-CHOP and Other Rituximab Combinations Explained
- Rituximab (MabThera, Ristova and biosimilars): The Complete Patient Guide
- Rituximab Infusion Day: Premedication, Duration and What to Expect
- Rituximab Infusion Reactions: Why the First Infusion Is Different
- Rituximab Maintenance: Two More Years of Infusions, and Why
- Rituximab Myths: Vaccines, Immunity and 'Permanent Damage'
- Rituximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Rituximab Side Effects: The Complete List and Timeline
- Rituximab Success Rate and Survival: An Honest Look at the Numbers
- Rituximab in Elderly Patients and Those With Other Illnesses
- Tests and Monitoring While You Are on Rituximab
- When Rituximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Rituximab? B-Cell Lymphoma and CLL
- Why the Same Drug Treats Arthritis and Lymphoma
- Will Insurance or a Government Scheme Pay for Rituximab?
- Work, Travel and Daily Life on Rituximab
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What happens if one of my blood test results comes back abnormal?
Your oncologist will interpret the result in context — a single mildly raised liver enzyme or a modestly low count often requires observation rather than immediate action. If the abnormality is significant, imatinib may be paused temporarily while the level recovers, then restarted, sometimes at a different dose. This is a planned part of how imatinib is managed, not a sign that treatment has failed. Reporting symptoms early is what gives your team the chance to act before an abnormal result becomes a serious one.
Do I need the BCR-ABL test if I am on imatinib for GIST rather than CML?
No. The BCR-ABL test measures suppression of the Philadelphia chromosome gene, which is the target in CML. GIST is driven by a different mutation — usually in KIT or PDGFRA — and is monitored differently, primarily through imaging such as CT or PET-CT rather than molecular blood tests. Your test schedule will be specific to your diagnosis, and your oncologist will explain exactly which tests apply to you.
Can I skip a blood test if I feel completely fine?
The reason for not skipping is precisely that feeling fine does not tell you what your blood counts are doing. Imatinib can lower white cells or platelets before any symptom appears. The test is not checking whether you feel well — it is checking whether the numbers are stable. Missing a test removes the early warning that allows a simple adjustment rather than a more complicated response later. If attending is genuinely difficult, call your team to rearrange rather than skip.
What does my BCR-ABL number actually mean?
The BCR-ABL PCR measures the proportion of cells in your blood that still carry the cancer-driving gene. The result is reported on an international scale as a percentage. A falling number over successive tests means imatinib is suppressing the leukaemia. A very low or undetectable result is called a deep molecular response. The direction of the trend over time matters more than any single result in isolation, and your oncologist will explain what your specific reading means in the context of your treatment history.
How long do I need to keep having monitoring tests?
For most people, monitoring continues for as long as imatinib is prescribed — which for CML is often many years. In a proportion of CML patients who achieve a sustained deep molecular response, a carefully supervised attempt to stop imatinib with close follow-up is now part of NCCN and ELN guidance. That decision is made jointly with your oncologist based on your full treatment history. For GIST, monitoring continues while the drug is working and the cancer remains controlled.